Singapore, Singapore

Time filter

Source Type

— This report studies the global Cancer Stem Cells (CSCs) market, analyzes and researches the Cancer Stem Cells (CSCs) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Janssen Qiagen Advanced Cell Diagnostics ApoCell Biofluidica Clearbridge Biomedics CytoTrack Celsee Fluxion Gilupi Cynvenio On-chip YZY Bio BioView Creatv MicroTech Fluidigm Ikonisys AdnaGen IVDiagnostics Miltenyi Biotec Aviva Biosciences Corporation ScreenCell Silicon Biosystems Market segment by Type, Cancer Stem Cells (CSCs) can be split into CellSearch Others Market segment by Application, Cancer Stem Cells (CSCs) can be split into Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment Some Points from Table of Content: Chapter One: Industry Overview of Cancer Stem Cells (CSCs) 1.1 Cancer Stem Cells (CSCs) Market Overview 1.1.1 Cancer Stem Cells (CSCs) Product Scope 1.1.2 Market Status and Outlook 1.2 Global Cancer Stem Cells (CSCs) Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Cancer Stem Cells (CSCs) Market by Type 1.3.1 CellSearch 1.3.2 Others 1.4 Cancer Stem Cells (CSCs) Market by End Users/Application 1.4.1 Breast Cancer Diagnosis and Treatment 1.4.2 Prostate Cancer Diagnosis and Treatment 1.4.3 Colorectal Cancer Diagnosis and Treatment 1.4.4 Lung Cancer Diagnosis and Treatment 1.4.5 Other Cancers Diagnosis and Treatment Chapter Two: Global Cancer Stem Cells (CSCs) Competition Analysis by Players 2.1 Cancer Stem Cells (CSCs) Market Size (Value) by Players (2016 and 2017) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future Chapter Three: Company (Top Players) Profiles 3.1 Janssen 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.1.5 Recent Developments 3.2 Qiagen 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.2.5 Recent Developments 3.3 Advanced Cell Diagnostics 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.3.5 Recent Developments 3.4 ApoCell 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.4.5 Recent Developments 3.5 Biofluidica 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.5.5 Recent Developments 3.6 Clearbridge Biomedics 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.6.5 Recent Developments 3.7 CytoTrack 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.7.5 Recent Developments 3.8 Celsee 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.8.5 Recent Developments 3.9 Fluxion 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.9.5 Recent Developments 3.10 Gilupi 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.10.5 Recent Developments 3.11 Cynvenio 3.12 On-chip 3.13 YZY Bio 3.14 BioView 3.15 Creatv MicroTech 3.16 Fluidigm 3.17 Ikonisys 3.18 AdnaGen 3.19 IVDiagnostics 3.20 Miltenyi Biotec 3.21 Aviva Biosciences Corporation 3.22 ScreenCell 3.23 Silicon Biosystems The Report Contains: 114 Pages. Make an enquire of this report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/288983 . For more information, please visit http://www.orbisresearch.com/reports/index/global-cancer-stem-cells-cscs-market-size-status-and-forecast-2022


Warkiani M.E.,Singapore Alliance for Research and Technology Center | Warkiani M.E.,Nanyang Technological University | Bhagat A.A.S.,Clearbridge Biomedics | Khoo B.L.,National University of Singapore | And 6 more authors.
ACS Nano | Year: 2013

Isoporous membranes are versatile structures with numerous potential and realized applications in various fields of science such as micro/nanofiltration, cell separation and harvesting, controlled drug delivery, optics, gas separation, and chromatography. Recent advances in micro/nanofabrication techniques and material synthesis provide novel methods toward controlling the detailed microstructure of membrane materials, allowing fabrication of membranes with well-defined pore size and shape. This review summarizes the current state-of-the-art for isoporous membrane fabrication using different techniques, including microfabrication, anodization, and advanced material synthesis. Various applications of isoporous membranes, such as protein filtration, pathogen isolation, cell harvesting, biosensing, and drug delivery, are also presented. © 2013 American Chemical Society.


Wiseguyreports.Com Adds “Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database This report studies sales (consumption) of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into CellSearch Others Type III Split by applications, this report focuses on sales, market share and growth rate of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in each application, can be divided into Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Report 2016 1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Overview 1.1 Product Overview and Scope of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.2 Classification of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.2.1 CellSearch 1.2.2 Others 1.2.3 Type III 1.3 Application of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.3.1 Breast Cancer Diagnosis and Treatment 1.3.2 Prostate Cancer Diagnosis and Treatment 1.3.3 Colorectal Cancer Diagnosis and Treatment 1.3.4 Lung Cancer Diagnosis and Treatment 1.3.5 Other Cancers Diagnosis and Treatment 1.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (2011-2021) 1.5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Growth Rate (2011-2021) 1.5.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) 7 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturers Analysis 7.1 Janssen 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Qiagen 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 124 Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 Advanced Cell Diagnostics 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 145 Product Type, Application and Specification 7.3.2.1 Type I 7.3.2.2 Type II 7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 ApoCell 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 7.4.2.1 Type I 7.4.2.2 Type II 7.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Biofluidica 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 7.5.2.1 Type I 7.5.2.2 Type II 7.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Clearbridge Biomedics 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 7.6.2.1 Type I 7.6.2.2 Type II 7.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 CytoTrack 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Chemical & Material Product Type, Application and Specification 7.7.2.1 Type I 7.7.2.2 Type II 7.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 Celsee 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 7.8.2.1 Type I 7.8.2.2 Type II 7.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 Fluxion 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 7.9.2.1 Type I 7.9.2.2 Type II 7.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Gilupi 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 7.10.2.1 Type I 7.10.2.2 Type II 7.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 Cynvenio 7.12 On-chip 7.13 YZY Bio 7.14 BioView 7.15 Creatv MicroTech 7.16 Fluidigm 7.17 Ikonisys 7.18 AdnaGen 7.19 IVDiagnostics 7.20 Miltenyi Biotec 7.21 Aviva Biosciences Corporation 7.22 ScreenCell 7.23 Silicon Biosystems 7.24 Global Other


Notes: Sales, means the sales volume of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue, means the sales value of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) This report studies sales (consumption) of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Janssen Qiagen Advanced Cell Diagnostics ApoCell Biofluidica Clearbridge Biomedics CytoTrack Celsee Fluxion Gilupi Cynvenio On-chip YZY Bio BioView Creatv MicroTech Fluidigm Ikonisys AdnaGen IVDiagnostics Miltenyi Biotec Aviva Biosciences Corporation ScreenCell Silicon Biosystems Global Other Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into CellSearch Others Type III Split by applications, this report focuses on sales, market share and growth rate of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in each application, can be divided into Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Report 2016 1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Overview 1.1 Product Overview and Scope of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.2 Classification of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.2.1 CellSearch 1.2.2 Others 1.2.3 Type III 1.3 Application of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 1.3.1 Breast Cancer Diagnosis and Treatment 1.3.2 Prostate Cancer Diagnosis and Treatment 1.3.3 Colorectal Cancer Diagnosis and Treatment 1.3.4 Lung Cancer Diagnosis and Treatment 1.3.5 Other Cancers Diagnosis and Treatment 1.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (2011-2021) 1.5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Growth Rate (2011-2021) 1.5.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) 2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Competition by Manufacturers, Type and Application 2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competition by Manufacturers 2.1.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Market Share of Key Manufacturers (2011-2016) 2.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Share by Manufacturers (2011-2016) 2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (Volume and Value) by Type 2.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Market Share by Type (2011-2016) 2.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Market Share by Type (2011-2016) 2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (Volume and Value) by Regions 2.3.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Market Share by Regions (2011-2016) 2.3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Market Share by Regions (2011-2016) 2.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) (Volume) by Application Figure Picture of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Table Classification of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Figure Global Sales Market Share of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by Type in 2015 Figure CellSearch Picture Figure Others Picture Table Applications of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Figure Global Sales Market Share of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by Application in 2015 Figure Breast Cancer Diagnosis and Treatment Examples Figure Prostate Cancer Diagnosis and Treatment Examples Figure Colorectal Cancer Diagnosis and Treatment Examples Figure Lung Cancer Diagnosis and Treatment Examples Figure Other Cancers Diagnosis and Treatment Examples Figure United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Figure China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Figure Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Figure Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Figure Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales and Growth Rate (2011-2021) Figure Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Growth Rate (2011-2021) Table Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales of Key Manufacturers (2011-2016) Table Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Share by Manufacturers (2011-2016) Figure 2015 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Share by Manufacturers Figure 2016 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Share by Manufacturers Table Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Manufacturers (2011-2016) Table Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Manufacturers (2011-2016) Table 2015 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Manufacturers FOR ANY QUERY, REACH US @ Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Global Market Research Report 2016


— This report mainly covers Circulating Tumor Cells products, by types (CTC enrichment, CTC detection and CTC analysis), by applications (Prostate Cancer, Breast Cancer, Colorectal Cancer Diagnosis and Treatment and Others). This report focuses on the Circulating Tumor Cells in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. For more information or any query mail at sales@wiseguyreports.com Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America, Middle East and Africa Market Segment by Applications, can be divided into Prostate Cancer Breast Cancer Colorectal Cancer Others There are 13 Chapters to deeply display the global Circulating Tumor Cells market. Chapter 2, to analyze the top manufacturers of Circulating Tumor Cells, with sales, revenue, and price of Circulating Tumor Cells, in 2015 and 2016; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016; Chapter 4, to show the global market by regions, with sales, revenue and market share of Circulating Tumor Cells, for each region, from 2011 to 2016; 2 Manufacturers Profiles 2.1 Janssen 2.1.1 Business Overview 2.1.2 Circulating Tumor Cells Type and Applications 2.1.2.1 Type 1 2.1.2.2 Type 2 2.1.3 Janssen Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.2 Qiagen(Adnagen) 2.2.1 Business Overview 2.2.2 Circulating Tumor Cells Type and Applications 2.2.2.1 Type 1 2.2.2.2 Type 2 2.2.3 Qiagen(Adnagen) Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.3 Acousys Biodevices, Inc 2.3.1 Business Overview 2.3.2 Circulating Tumor Cells Type and Applications 2.3.2.1 Type 1 2.3.2.2 Type 2 2.3.3 Acousys Biodevices, Inc Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.4 ApoCell 2.4.1 Business Overview 2.4.2 Circulating Tumor Cells Type and Applications 2.4.2.1 Type 1 2.4.2.2 Type 2 2.4.3 ApoCell Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.5 Advanced Cell Diagnostics 2.5.1 Business Overview 2.5.2 Circulating Tumor Cells Type and Applications 2.5.2.1 Type 1 2.5.2.2 Type 2 2.5.3 Advanced Cell Diagnostics Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.6 Fluxion Biosciences 2.6.1 Business Overview 2.6.2 Circulating Tumor Cells Type and Applications 2.6.2.1 Type 1 2.6.2.2 Type 2 2.6.3 Fluxion Biosciences Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.7 Biocept 2.7.1 Business Overview 2.7.2 Circulating Tumor Cells Type and Applications 2.7.2.1 Type 1 2.7.2.2 Type 2 2.7.3 Biocept Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.8 Fluidigm 2.8.1 Business Overview 2.8.2 Circulating Tumor Cells Type and Applications 2.8.2.1 Type 1 2.8.2.2 Type 2 2.8.3 Fluidigm Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.9 Epic Sciences 2.9.1 Business Overview 2.9.2 Circulating Tumor Cells Type and Applications 2.9.2.1 Type 1 2.9.2.2 Type 2 2.9.3 Epic Sciences Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.10 Clearbridge Biomedics 2.10.1 Business Overview 2.10.2 Circulating Tumor Cells Type and Applications 2.10.2.1 Type 1 2.10.2.2 Type 2 2.10.3 Clearbridge Biomedics Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.11 Cynvenio 2.11.1 Business Overview 2.11.2 Circulating Tumor Cells Type and Applications 2.11.2.1 Type 1 2.11.2.2 Type 2 2.11.3 Cynvenio Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.12 CytoTrack 2.12.1 Business Overview 2.12.2 Circulating Tumor Cells Type and Applications 2.12.2.1 Type 1 2.12.2.2 Type 2 2.12.3 CytoTrack Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.13 ScreenCell 2.13.1 Business Overview 2.13.2 Circulating Tumor Cells Type and Applications 2.13.2.1 Type 1 2.13.2.2 Type 2 2.13.3 ScreenCell Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.14 Creatv Microtech 2.14.1 Business Overview 2.14.2 Circulating Tumor Cells Type and Applications 2.14.2.1 Type 1 2.14.2.2 Type 2 2.14.3 Creatv Microtech Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.15 Aviva Biosciences 2.15.1 Business Overview 2.15.2 Circulating Tumor Cells Type and Applications 2.15.2.1 Type 1 2.15.2.2 Type 2 2.15.3 Aviva Biosciences Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.16 Greiner Bio-one GmbH 2.16.1 Business Overview 2.16.2 Circulating Tumor Cells Type and Applications 2.16.2.1 Type 1 2.16.2.2 Type 2 2.16.3 Greiner Bio-one GmbH Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.17 Sysmex Corporation 2.17.1 Business Overview 2.17.2 Circulating Tumor Cells Type and Applications 2.17.2.1 Type 1 2.17.2.2 Type 2 2.17.3 Sysmex Corporation Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.18 Ikonisys 2.18.1 Business Overview 2.18.2 Circulating Tumor Cells Type and Applications 2.18.2.1 Type 1 2.18.2.2 Type 2 2.18.3 Ikonisys Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


SINGAPORE and Santa Monica, Calif., Nov 10, 2016 /PRNewswire/ -- The John Wayne Cancer Institute (JWCI) at the St. Johns Health Center, Providence Health Systems in Santa Monica California and Singapore-based Clearbridge BioMedics today announced a research partnership to establish a Circulating Tumor Cell Center of Research Excellence (CTC CoRE). This new center builds upon JWCI's pioneering experience in CTC assessment in patients and Clearbridge BioMedics' expertise in isolating CTCs. Targeted to be set up by November 2016, the initial focus of the CTC CoRE is on melanoma, followed by epithelial cancers. JWCI envision that in the future, the center will evolve into a CLIA[1] service for testing blood biopsy samples, with the objective of supporting diagnosis, treatment monitoring, and developing personalized therapies. This CTC CoRE leverages on JWCI's molecular CTC assay development expertise from rare cells and Clearbridge Biomedics' ClearCell® FX System for unbiased, label-free enrichment of CTCs. The research carried out at the CTC CoRE aims to use defined tumor-related DNA and RNA biomarkers established at JWCI to assess patient status before and after therapy, for example, at the time of tumor resection, before and after use of specific therapeutic drugs, or for general follow-up. This may aid clinicians to monitor tumor progression and patients' response to treatment. Work carried out at this new CTC CoRE is expected to lead to validation of several assays for use under JWCI's future CLIA program, beginning with melanoma, and followed by epithelial solid tumor cancers. This is expected to eventually result in better decision-making and significant cost savings. The program allows for unbiased and label-free isolation of CTCs in a robust and reproducible manner compatible with multiple types of downstream assays used for clinical oncology translational studies. The ClearCell® FX System is one of the world's first automated CTC retrieval systems, powered by the patented CTChip® FR1 inertial microfluidics biochip. Using a label-free approach, the ClearCell® FX System retrieves wholly-intact and viable CTCs from a standard blood draw. The ClearCell® FX System provides cost-effective retrieval of CTCs proven to work with applications used in research and the clinic, such as Next Generation Sequencing (NGS), PCR, Fluorescent in-situ hybridization (FISH) and Immunofluorescence staining. "This partnership is an expansion of our long-standing collaboration with Clearbridge BioMedics. We originally began working with them in 2011, to validate the ClearCell® FX System, and we are delighted to be setting up a new CTC Core with Clearbridge BioMedics to advance the development of our assays. We hope to be able to transform this center into a CLIA service in early 2018" said Professor Dave SB Hoon, Director, Dept. Translational Molecular Medicine, JWCI. "We are honored to partner with JWCI, a leading research and treatment cancer institute. This is the second CTC CoRE that Clearbridge BioMedics has set up - the first being with the National Cancer Centre Singapore and Singapore General Hospital in 2014. Clearbridge BioMedics will continue working towards validation of clinical utility of our ClearCell® FX System, to help oncologists have access to better tools to diagnose, treat and manage cancer," said Dr Michael Paumen, CEO Clearbridge BioMedics. In 1991, the John Wayne Cancer Institute (JWCI) launched a successful affiliation with Saint John's Health Center and opened in Santa Monica, Ca. Combined with the exceptional quality of Saint John's medical staff and hospital, a unique cancer institute was created, outstanding in the areas of translational oncology research, innovative surgery oncology approaches and medical immune-oncology. JWCI is one of three cancer centers of the Providence Health Systems on the west coast of the USA consisting of 50 hospitals from Alaska to Southern California. With renowned researchers and advanced technologies, JWCI has the unique ability to quickly and effectively react, explore, and investigate life-saving cancer treatments. Developed at the Institute, the Sentinel Node Biopsy is one such treatment. Now considered the worldwide standard of care for melanoma and breast cancer, the Sentinel Node Biopsy has revolutionized treatment options by offering a minimally invasive technique to determine the spread of tumor cells. JWCI has a strong global oncology program through its multicentre trials and collaborations with many outstanding cancer centers in the world. Clearbridge BioMedics Pte Ltd. is a clinical stage cancer diagnostics company that develops and manufactures liquid biopsy systems. The Company is based in Singapore and has commercially launched the ClearCell Fx platform sales to clinical research centers around the globe. The Company has won numerous awards and garnered global recognition for its novel Circulating Tumor Cell (CTC) detection platform technology, the ClearCell® FX System. Clearbridge BioMedics has received ISO 13485 certification in 2011 and the ClearCell® FX attained CE IVD in 2015. ClearCell® FX System and its biochip are utilizing state-of-the-art, non-invasive liquid biopsy to analyze blood samples for circulating tumor cells (CTCs), the device allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of targeted cancer therapies. www.clearbridgebiomedics.com [1] In accordance with the Clinical Laboratory Improvement Amendment (CLIA), the CLIA Program sets standards and issues certificates for clinical laboratory testing. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/john-wayne-cancer-institute-and-clearbridge-biomedics-announce-partnership-to-develop-circulating-tumor-cell-centre-of-research-excellence-in-the-us-300356644.html


Patent
Clearbridge Biomedics | Date: 2013-10-16

A microfluidic device is disclosed. The device comprises at least one inlet for receiving circulating tumor cells and other cells in a sample; at least one curvilinear and/or spiral channel through which the sample is caused to undergo partial or complete Dean cycles to isolate the circulating tumor cells from the other cells; and at least one outlet configured to communicate with the channel for providing the isolated circulating tumor cells. The channel is configured to provide a predetermined Force ratio based on a desired threshold cell size of the circulating tumor cells. A corresponding method of manufacturing of the device, and a related diagnostic system are also disclosed.


Patent
Clearbridge Biomedics | Date: 2014-10-16

An interface comprising: a plurality of external ports configured to fluidically communicate with a plurality of ports of a fluidic delivery platform; and a plurality of engaging conduits configured to fluidically communicate with a plurality of ports of a microfluidic biochip, wherein a tolerance of both the plurality of external ports and/or the plurality of engaging conduits is significantly tighter than a tolerance of the plurality of ports of the microfluidic biochip.


News Article | September 21, 2015
Site: www.techinasia.com

A third installment of Singapore’s state-run Early Stage Venture Fund (ESVF-III) was announced today during TechVenture 2015, a conference organized by the country’s National Research Foundation (NRF). This latest tranche of the fund targeting the venture capital market will pour S$40 million (US$28.4 million) into establishing corporate venture funds by large local enterprises (LLEs). Dr. Vivian Balakrishnan, Singapore’s Minister for the Environment and Water Resources and Minister-in-charge of the country’s Smart Nation initiative, made the announcement during the event’s opening speech this morning. The idea is to help small, high-tech companies in Singapore grow through co-investments by the Singapore government and local private-sector players. According to the NRF, this allows for a technology ecosystem of small companies to grow around the larger ones that are putting in the money. This allows corporations to benefit from the technological innovations these smaller startups specialize in, while startups can tap into the resources and networks that larger firms have at their disposal. The ESVF was established in 2008 by the NRF in order to encourage researchers to commercialize their research ideas and help entrepreneurs establish and grow technology-based companies. The fund brings in venture capital firms to help grow the ecosystem by matching VC investments in early-stage tech startups on a 1:1 basis. Before this third installment, the fund had invested a total of S$100 million (US$71 million) into Singapore-based startups. During the first installment, it matched funds with VC firms Bioveda Capital, Extream Ventures, New Asia Investments, Raffles Venture Partners, and Walden International. For the second installment, it teamed up with Jungle Ventures, Golden Gate Ventures, SBI Ven Capital, Walden International, and Monk’s Hill Ventures. Notable startups that were funded by the ESVF and have successfully exited include YFind, HungryGoWhere, Brandtology, and JustCommodity, while others, such as Clearbridge Biomedics and Aslan Pharmaceuticals, received significant B-round investments. Other notable announcements during the first day of TechVenture include the SG-UK Joint Test-Bedding Initiative, implemented under the UK-Singapore Innovation and Research Partnership Agreement signed in October 2014. Under the agreement, small- and medium-sized enterprises from the UK and Singapore can pursue and establish partnerships with each other’s companies, universities, and organizations, in order to develop technologies for sustainable urban development. Finally, the NRF announced the establishment of the Lux Photonics Consortium, an alliance to develop collaboration between different institutes of higher learning in Singapore and private-sector players, to double down on photonics research. This particular area of research includes development of infrastructure for breakneck internet speeds by using new fiber-optic cables or electronic circuits powered by light. The NRF has invested around S$75 million (US$53.3 million) in grants for photonics research to Singapore’s Nanyang Technological University, National University of Singapore, and research and technology giant A*STAR. The institutes have partnered with the NRF and seven private-sector companies in establishing the consortium.

Loading Clearbridge Biomedics collaborators
Loading Clearbridge Biomedics collaborators